Lena Brandefors

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

Magnus Tobiasson, I Dybedahl, Mette Skov Holm et al. · Blood Cancer Journal · 2014 · 55 citations · Full text

Medicine, Hematology, Pharmacology +17

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia

Christian Buske, Meletios Α. Dimopoulos, Alexander Grunenberg et al. · Journal of Clinical Oncology · 2023 · 41 citations

Medicine, Oncology, Pharmacology +14

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

Marlijn Hoeks, Timothy Bagguley, Corine van Marrewijk et al. · Leukemia · 2020 · 28 citations · Full text

Medicine, Hematology, Iron Metabolism Disorders +14

Prognostic factors and primary treatment for Waldenström macroglobulinemia – a Swedish Lymphoma Registry study

Lena Brandefors, Beatrice Melin, Jack Lindh et al. · British Journal of Haematology · 2018 · 17 citations · Full text

Medicine, Oncology, Chemotherapy +10

Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial

Christian Buske, Meletios Α. Dimopoulos, Alexander Grunenberg et al. · Blood · 2020 · 16 citations

Medicine, Hematology, Pharmacotherapy +10